Greg Sullivan

Greg Sullivan, MD, who co-founded Bridge Therapeutics with the goal of helping patients beyond the walls of his own medical practice, has 25 years of experience conducting human studies for new drugs. Since 2003, he has performed numerous buprenorphine studies, including FDA safety and efficacy studies for every buprenorphine product currently approved for the U.S. market. He is board-certified in both addiction medicine and internal medicine and treats chronic pain patients at his practice in Birmingham, Ala.